AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...

Dr. Bob Li, a top Asian leader from the New York-based Memorial Sloan Kettering Cancer Center, has become global head of ...

which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...

(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

We recently published a list of the 10 Most Profitable European Stocks to Invest In. In this article, we are going to take a ...